AI Integration Opportunities Tempus's active collaborations with Median Technologies to incorporate AI-powered diagnostic tools like eyonis® LCS into clinical workflows present a strong opportunity to provide supplementary AI solutions or customization services that enhance precision medicine and oncology diagnostics.

Expanding Market Reach With Tempus's recent strategic collaborations and regulatory developments to expand access to AI-based cancer detection software in the US, sales efforts can focus on medical device distributors, healthcare providers, and clinical laboratories looking to adopt innovative AI-driven diagnostics.

Growth and Investment The company’s reported revenue growth of 83% and record data sales in 2025 highlight a rapidly expanding customer base and increasing demand for precision medicine solutions, indicating potential for upselling existing clients and targeting new healthcare institutions.

Funding and Investor Interest The increased investment by notable funds like the New York State Common Retirement Fund reflects strong institutional confidence, suggesting opportunities to approach similar large-scale investors or partners interested in scaling AI healthcare initiatives.

Technology Stack Leverage Tempus’s utilization of advanced technologies including AI, SaaS, and imaging platforms indicates an openness to innovative integrations, providing sales prospects for complementary tech providers and enterprise software solutions targeted at healthcare AI ecosystems.